Literature DB >> 15963014

Tailoring access to high cost, genetically targeted drugs.

Wayne D Hall, Robyn Ward, Winston S Liauw, Christine Y Lu, Jo-anne E Brien.   

Abstract

Assessment of real cost effectiveness, with data linked to individual health outcomes while protecting patient privacy, is an essential challenge we need to meet.

Entities:  

Mesh：

Year:  2005        PMID： 15963014     DOI： 10.5694/j.1326-5377.2005.tb06844.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN： 0025-729X            Impact factor:   7.738


  8 in total

1.  Public views on priority setting for high cost medications in public hospitals in Australia.

Authors:  Gisselle Gallego; Susan J Taylor; Paul McNeill; Jo-anne E Brien
Journal:  Health Expect       Date:  2007-09       Impact factor: 3.377

2.  Pharmacists' role in targeted cancer therapy in Australia and implications for pharmacy education.

Authors:  David M Plevin; Helena M Ward; Michael B Ward; Michael J Sorich; Ross A McKinnon
Journal:  Am J Pharm Educ       Date:  2010-11-10       Impact factor: 2.047

3.  Media influence on Herceptin subsidization in Australia: application of the rule of rescue?

Authors:  Ross Mackenzie; Simon Chapman; Glenn Salkeld; Simon Holding
Journal:  J R Soc Med       Date:  2008-06       Impact factor: 5.344

Review 4.  The evolution of Taiwan's National Health Insurance drug reimbursement scheme.

Authors:  Jason C Hsu; Christine Y Lu
Journal:  Daru       Date:  2015-02-10       Impact factor: 3.117

5.  Longitudinal trends in use of targeted therapies for treatment of malignant neoplasms of the eye: a population-based study in Taiwan.

Authors:  Jason C Hsu; Luis A Gonzalez-Gonzalez; Vicky H Lu; Christine Y Lu
Journal:  BMJ Open       Date:  2016-05-27       Impact factor: 2.692

6.  Access to high cost medicines in Australia: ethical perspectives.

Authors:  Christine Y Lu; Paul Macneill; Ken Williams; Ric Day
Journal:  Aust New Zealand Health Policy       Date:  2008-05-19

7.  Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study.

Authors:  Jason C Hsu; Christine Y Lu
Journal:  BMJ Open       Date:  2016-06-06       Impact factor: 2.692

8.  Geographic Variations and Time Trends in Cancer Treatments in Taiwan.

Authors:  Jason C Hsu; Sheng-Mao Chang; Christine Y Lu
Journal:  BMC Public Health       Date:  2017-08-02       Impact factor: 3.295
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.